Home Ricerca Sedi Chi siamo Organigramma Personale Contatti Didattica Login Documenti EN
Progetti in evidenza
INCIPIT
(Link esterno)

ISTAPCA
(1209 visite)

Fondo Europeo Pesca
(622 visite)

Euro-BioImaging
(Link esterno)

Fondazione Veronesi
(Link esterno)

LightDyNAmics
(1094 visite)

 INMiND
(1186 visite)

Instruct-IT
(Link esterno)

 PRIN
(1329 visite)

 eHealthNet
(1090 visite)

Ponrec
(1028 visite)

MFAG Grant
(1134 visite)

MERIT
(Link esterno)


Collegamenti

Contiene: [X]      Estesa     Autori: [X]  Tipo di lavoro: [X]
Data iniziale: Data finale: [X]      Sede: Affiliazione IBB     
    
[Pulisci modulo]



Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90 (162 visite)

Nardelli A, Castaldi E, Ortosecco G, Speranza A, Storto G, Pace L, Salvatore M

Applied Radiation And Isotopes (ISSN: 1872-9800, 0969-8043, 0969-8043linking), 2011 Jan; 69(1): 52-55.



Tipo di articolo: Journal Article,

Impact factor: 1.172, Impact factor a 5 anni: 1.202

Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-77958459740&partnerID=40&md5=69dab00885bf42b303bb2309235ad484

Parole chiave: 90y, Dota-Peptides, Radiolabelling, Radionuclide Therapy, 90< Sup>y, Critical Factors, Effective Therapy, High Activity, Impact Reaction, Peptide Receptor, Radiochemical Yield, Reaction Conditions, Reaction Temperature, Specific Activity, Statistically Significant Difference, Temperature Constant, Water Baths, Yttrium-90, Association Reactions, Group Technology, High Performance Liquid Chromatography, Quality Control, Radioisotopes, Thin Layer Chromatography, Yttrium Alloys, Reaction Kinetics, 10 Tetraazacyclododecane 1, 10 Tetraacetic Acid, Article, Chemical Reaction Kinetics, Controlled Study, Isotope Labeling, Priority Journal, Radioactivity, Radiochemistry, Heterocyclic Compounds, 1-Ring, Humans, Octreotide, Organometallic Compounds, Radiopharmaceuticals, Yttrium Radioisotopes, 1-Ring Chemistry , Isotope Labeling Methods , Octreotide Analogs, Derivatives Chemistry , Organometallic Compounds Chemical Synthesis , Radiopharmaceuticals Chemical Synthesis , Yttrium Radioisotopes Chemistry,

Affiliazioni:

*** IBB - CNR ***
Istituto di Biostrutture e Bioimmagini, Consiglio Nazionale delle Ricerche (CNR), Naples, Italy. a.nardelli@libero.it
IRCCS-CROB, Rionero in Vulture, Italy
Dipartimento di Scienze Biomorfologiche e Funzionali, Università Federico II, Via Pansini 5, 80131 Naples, Italy



Riferimenti:

Breeman, W.A., de Jong, M., Kwekkeboom, D.J., Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives (2001) Eur. J. Nucl. Med., 28, p. 142

Bunemann, M., Hosey, M.M., G-protein coupled receptor kinases as modulators of G-protein signalling (1999) J. Physiol., 517, p. 5

De Jong, M., Valkema, R., Jamar, F., Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings (2002) Semin Nucl. Med., 32, p. 133

Esser, J.P., Krenning, E.P., Teunissen, J.J., Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT? (2006) Eur. J. Nucl. Med. Mol. Imaging, 33, p. 1346

Forrer, F., Uusijärvi, H., Waldherr, C., A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours (2004) Eur. J. Nucl. Med. Mol. Imaging, 31, p. 1257

Kwekkeboom, D., Krenning, E.P., de Jong, M., Peptide receptor imaging and therapy (2000) J. Nucl. Med., 41, p. 1704

Krenning, E.P., Valkema, R., Kooij, P.P., The role of radioactive somatostatin and its analogues in the control of tumor growth (2000) Recent Results Cancer Res., 153, p. 1

Kwekkeboom, D.J., Bakker, W.H., Kooij, P.P., [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients (2001) Eur. J. Nucl. Med., 28, p. 1319

Kukis, D.L., DeNardo, S.J., DeNardo, G.L., Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates (1998) J. Nucl. Med., 39, p. 2105

Liu, S., Cheung, E., Ziegler, M.C., (90)Y and (177)Lu labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy (2001) Bioconjugate Chem., 12, p. 559

Oberg, K., Kvols, L., Caplin, M., Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system (2004) Ann. Oncol., 15, p. 966

Plöckinger, U., Rindi, G., Arnold, R., European Neuroendocrine Tumour Society.Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS) (2004) Neuroendocrinology, 80, p. 394

Wild, D., Schmitt, J.S., Gini, M., DOTANOC, a high-affinity ligand of somatostatin receptors subtypes 2, 3 and 5 for labelling with various radiometals (2003) Eur. J. Nucl. Med., 30, p. 1338

Breeman, W. A., de Jong, M., Kwekkeboom, D. J., Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives (2001) Eur. J. Nucl. Med., 28, p. 142

Esser, J. P., Krenning, E. P., Teunissen, J. J., Comparison of [(177) Lu-DOTA (0), Tyr (3)] octreotate and [(177) Lu-DOTA (0), Tyr (3)] octreotide: which peptide is preferable for PRRT? (2006) Eur. J. Nucl. Med. Mol. Imaging, 33, p. 1346

Forrer, F., Uusij rvi, H., Waldherr, C., A comparison of (111) In-DOTATOC and (111) In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours (2004) Eur. J. Nucl. Med. Mol. Imaging, 31, p. 1257

Krenning, E. P., Valkema, R., Kooij, P. P., The role of radioactive somatostatin and its analogues in the control of tumor growth (2000) Recent Results Cancer Res., 153, p. 1

Kwekkeboom, D. J., Bakker, W. H., Kooij, P. P., [177Lu-DOTAOTyr3] octreotate: comparison with [111In-DTPAo] octreotide in patients (2001) Eur. J. Nucl. Med., 28, p. 1319

Kukis, D. L., DeNardo, S. J., DeNardo, G. L., Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates (1998) J. Nucl. Med., 39, p. 2105

Pl ckinger, U., Rindi, G., Arnold, R., European Neuroendocrine Tumour Society. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS) (2004) Neuroendocrinology, 80, p. 394



Peptide receptor radionuclide therapy (PRRT) has recently expanded due to radiolabelling of DOTA-peptides, such as the somatostatin analogues [DOTA0, Tyr3]octreotate (DOTATATE).The achievement of high specific activities during procedures has been indicated as the critical factor to consent effective therapy. Several radiochemical factors may negatively impact reaction procedures such as pH, temperature and time of reaction. Our study was undertaken to explore the influence of radiochemical parameters, such as time of incubation, on reaction kinetics during the radiolabelling of DOTATATE with 90Y. Methods: Forty-five radiolabelling procedures were carried out using small volumes of yttrium-90, typically 60-78 γL. At nearly constant pH and temperature two different settings of radiolabelling procedures were implemented, removing the products from the heating water bath approximately after 30. min (group E, early; n=20) and after 39. min (group L, later; n=25). Quality controls were performed by means of both high-performance liquid chromatography (HPLC) and thin-layer chromatography (TLC). Results: Reaction kinetics for 90Y were found to a provide suitable percentage of incorporation at pH 4.5 for both groups. Reaction temperature was not different between groups E and L. A significant difference was found between the two groups in radiochemical yield, which was 95.6%±0.8 for group E and 98.2%±1.1 for group L (p<0.0001). The specific activity of the final product was 46.9MBq/nmol. Conclusion: In order to achieve optimal specific activities, pH, temperature and time of reaction necessitate careful evaluation and setting. A statistically significant difference in labelling yield was found between a set of procedures completed at 39. min as compared to that executed at 30. min, keep the reaction pH and temperature constant. © 2010 Elsevier Ltd.
Nessun risultato.
Nessun risultato.
y"+OR+"Critical+Factors"+OR+"Effective+Therapy"+OR+"High+Activity"+OR+"Impact+Reaction"+OR+"Peptide+Receptor"+OR+"Radiochemical+Yield"+OR+"Reaction+Conditions"+OR+"Reaction+Temperature"+OR+"Specific+Activity"+OR+"Statistically+Significant+Difference"+OR+"Temperature+Constant"+OR+"Water+Baths"+OR+"Yttrium+90"+OR+"Association+Reactions"+OR+"Group+Technology"+OR+"High+Performance+Liquid+Chromatography"+OR+"Quality+Control"+OR+"Radioisotopes"+OR+"Thin+Layer+Chromatography"+OR+"Yttrium+Alloys"+OR+"Reaction+Kinetics"+OR+"10+Tetraazacyclododecane+1"+OR+"10+Tetraacetic+Acid"+OR+"Article"+OR+"Chemical+Reaction+Kinetics"+OR+"Controlled+Study"+OR+"Isotope+Labeling"+OR+"Priority+Journal"+OR+"Radioactivity"+OR+"Radiochemistry"+OR+"Heterocyclic+Compounds"+OR+"1+Ring"+OR+"Humans"+OR+"Octreotide"+OR+"Organometallic+Compounds"+OR+"Radiopharmaceuticals"+OR+"Yttrium+Radioisotopes"+OR+"1+Ring+Chemistry "+OR+"Isotope+Labeling+Methods "+OR+"Octreotide+Analogs"+OR+"Derivatives+Chemistry "+OR+"Organometallic+Compounds+Chemical+Synthesis "+OR+"Radiopharmaceuticals+Chemical+Synthesis "+OR+"Yttrium+Radioisotopes+Chemistry">Cerca bibliografia collegata su PubMed

Contiene: [X]      Estesa     Autori: [X]  Tipo di lavoro: [X]
Data iniziale: Data finale: [X]      Sede: Affiliazione IBB     
    
[Pulisci modulo]


Caporale A, Bolzati C, M , Incisivo G, Salvarese N, Grieco P, Ruvo M
* Improved synthesis on SPPS of dithiocarbamic cRGD-derivative and its application in 99mTc-radiolabelling (48 visite)
Peptide Science, 2018; N/D: N/D-N/D.
Impact Factor: 1.546
Dettagli    Esporta in BibTeX    Esporta in EndNote

Yousif AM, Minopoli M, Bifulco K, Ingangi V, Di Carluccio G, Merlino F, Motti ML, Grieco P, Carriero MV
* Cyclization of the urokinase receptor-derived Ser-Arg-Ser-Arg-Tyr peptide generates a potent inhibitor of trans-endothelial migration of monocytes (142 visite)
Plosone (ISSN: 1932-6203, 1932-6203electronic), 2015; 10(5): N/D-N/D.
Impact Factor: 3.057
Dettagli    Esporta in BibTeX    Esporta in EndNote

Ringhieri P, Iannitti R, Nardon C, Palumbo R, Fregona D, Morelli G, Accardo A
* Target selective micelles for bombesin receptors incorporating Au(III)-dithiocarbamato complexes (140 visite)
Int J Pharm (ISSN: 0378-5173, 1873-3476), 2014 Oct 1; 473(1-2): 194-202.
Impact Factor: 3.65
Dettagli    Esporta in BibTeX    Esporta in EndNote

Gallicchio R, Giacomobono S, Nardelli A, Pellegrino T, Simeon V, Gattozzi D, Maddalena F, Mainenti PP, Storto G
* Palliative Treatment Of Bone Metastases With Samarium-153 Edtmp At Onset Of Pain (126 visite)
Journal Of Bone And Mineral Metabolism (ISSN: 1435-5604, 0914-8779, 0914-8779linking), 2014 Jul; 32(4): 434-440.
Impact Factor: 2.46
Dettagli    Esporta in BibTeX    Esporta in EndNote

Storto G, Gallicchio R, Pellegrino T, Nardelli A,  De Luca S, Capacchione D, Sirignano C, Pace L
* Impact of F-18-fluoride PET-CT on implementing early treatment of painful bone metastases with Sm-153 EDTMP (111 visite)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897, 0969-8051linking), 2013 May; 40(4): 518-523.
Impact Factor: 2.408
Dettagli    Esporta in BibTeX    Esporta in EndNote

Accardo A, Salsano G, Morisco A, Aurilio M, Parisi A, Maione F, Cicala C, Tesauro D, Aloj L, De Rosa G, Morelli G
* Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: A potential theranostic agent (146 visite)
Int J Nanomed (ISSN: 1176-9114, 1178-2013, 1178-2013electronic), 2012; 7: 2007-2017.
Impact Factor: 3.463
Dettagli    Esporta in BibTeX    Esporta in EndNote

Nardelli A, Castaldi E, Ortosecco G, Speranza A, Storto G, Pellegrino T, Pace L, Salvatore M
* Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of Yttrium-90 (126 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2009 Sep; 36: N/D-N/D.
Impact Factor: 4.531
Dettagli    Esporta in BibTeX    Esporta in EndNote

Speranza A, Ortosecco G, Castaldi E, Nardelli A, Pace L, Salvatore M
* Fully automated synthesis procedure of 4-[18F]fluorobenzaldehyde by commercial synthesizer: amino-oxi peptide labelling prosthetic group (103 visite)
Applied Radiation And Isotopes (ISSN: 1872-9800, 0969-8043, 0969-8043linking), 2009 Sep; 67(9): 1664-1669.
Impact Factor: 1.094
Dettagli    Esporta in BibTeX    Esporta in EndNote

Carriero MV, Longanesi-cattani I, Bifulco K, Maglio O, Lista L, Barbieri A, Votta G, Masucci MT, Arra C, Franco R, De Rosa M, Stoppelli MP, Pavone V
* Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis (136 visite)
Mol Cancer Ther Molecular Cancer Therapeutics (ISSN: 1535-7163, 1538-8514electronic, 1535-7163linking), 2009 Sep; 8(9): 2708-2717.
Impact Factor: 4.953
Dettagli    Esporta in BibTeX    Esporta in EndNote

Storto G, Erra P, Pellegrino T, Nardelli A, Milone F, Di Giorgio E, Faggiano A, Castaldi E, Ortosecco G, Speranza A, Klain M, Colao A, Salvatore M, Pace L
* Efficacy and Toxicity of Peptide Receptor Radionuclide Therapy (PRRT) using medium-high activities of Y-90-DOTA-Octreotate (Y-90-DOTATATE) in patients with tumours expressing somatostatin receptors (SSTR) (102 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2008 Oct; 35: N/D-N/D.
Impact Factor: 4.532
Dettagli    Esporta in BibTeX    Esporta in EndNote

Bifulco K, Longanesi-cattani I, Gargiulo L, Maglio O, Cataldi M, De Rosa M, Stoppelli MP, Pavone V, Carriero MV
* An urokinase receptor antagonist that inhibits cell migration by blocking the formyl peptide receptor (84 visite)
Febs Lett (ISSN: 0014-5793print, 0014-5793linking, 1873-3468electronic), 2008 Apr 2; 582(7): 1141-1146.
Impact Factor: 3.264
Dettagli    Esporta in BibTeX    Esporta in EndNote

Storto G, Speranza A, Pellegrino T, Panico M, Cella L, Nardelli A, Russo AA, Klain M, Soricelli A, Pace L, Salvatore M
* Activity Threshold Determining Cumulative Aderse-Effects In Patients Undergoing Peptide Receptor Radionuclide Therapy With Y-90 Octreotate (108 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2006; 33: 338-338.
Impact Factor: 4.041
Dettagli    Esporta in BibTeX    Esporta in EndNote



12 Records (8 escludendo Abstract e Conferenze).
Impact factor totale: 38.999 (23.487 escludendo Abstract e Conferenze).
Impact factor a 5 anni totale: 39.655 (23.58 escludendo Abstract e Conferenze).







    Esporta in BibTeX    Esporta in EndNote

Ultima modifica di Marco Comerci in data Thursday 19 March 2015, 12:24:54
162 visite. Ultima visita in data Saturday 29 December 2018, 21:58:39

Webmaster and developer: Marco Comerci
Per problemi e suggerimenti: adminibb.cnr.it
Ultimo aggiornamento: Wednesday 23 January 2019, 14:05:01